The management of patients with atrial fibrillation requiring PCI and is an evolving and fascinating topic, not only for those who are interested in antithrombotic therapy.
The duration of aspirin therapy, now limited to up to a maximum of 1 month in patients with prevailing thrombotic risk with a proposed default duration of one week; the selection of P2Y12 inhibitors (mostly clopidogrel); and the clear advantage of direct oral anticoagulant (OAC) over vitamin K antagonists in the vast majority of patients, are now emerging as preferred approaches in most patients but with the necessity of accurate quantification of the risk of both thrombosis and bleeding to personalize therapeutic decisions.
I hope this selection may help inform the treatment of your next patient.
Assoc. Prof. Sergio Leonardi, FESC
Resources below have been selected by Dr. Michael D. Spartalis
ACVC Clinical Decision-Making Toolkit
Acute Cardiovascular Care Congress Resources
A selection of resources from Acute Cardiovascular Care 2019:
- Positioning of the topic - DAT for all ACS patients with atrial fibrillation receiving coronary stents
- New-onset atrial fibrillation is more severe than pre-existing atrial fibrillation in patients with acute coronary syndrome: a meta-analysis
- Antithrombotic treatment in patients with new-onset atrial fibrillation after acute coronary syndrome
ACVC Webinars on:
- P2Y12-inhibitors in NSTEMI - old and new guidelines
- The trial of the trials: AUGUSTUS vs ENTRUST AF PCI: from trial design to clinical implications
ESC Clinical Practice Guidelines
- 2020 Acute Coronary Syndromes (ACS) in Patients Presenting without Persistent ST-Segment Elevation (Management of) Guidelines
- 2020 Atrial Fibrillation (Management of) Guidelines